These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34486922)

  • 41. Severe form of type 2 reaction in patients of Hansen's disease after withdrawal of thalidomide: case reports.
    Rattan R; Shanker V; Tegta GR; Verma GK
    Indian J Lepr; 2009; 81(4):199-203. PubMed ID: 20704076
    [TBL] [Abstract][Full Text] [Related]  

  • 42. No role for thalidomide in the treatment of leprosy.
    Crawford CL
    J Infect Dis; 2006 Jun; 193(12):1743-4; author reply 1744-5. PubMed ID: 16703522
    [No Abstract]   [Full Text] [Related]  

  • 43. Does thalidomide have a role in leprosy?
    Crawford CL
    Lancet; 2004 Jun; 363(9424):1911. PubMed ID: 15183644
    [No Abstract]   [Full Text] [Related]  

  • 44. Control of endometriosis-associated pain with etonogestrel-releasing contraceptive implant and 52-mg levonorgestrel-releasing intrauterine system: randomized clinical trial.
    Carvalho N; Margatho D; Cursino K; Benetti-Pinto CL; Bahamondes L
    Fertil Steril; 2018 Nov; 110(6):1129-1136. PubMed ID: 30396557
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Thalidomide levels in patients with erythema nodosum leprosum.
    Vieira JL; Valente Mdo S
    Ther Drug Monit; 2009 Oct; 31(5):602-3. PubMed ID: 19704404
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of thalidomide in the management of erythema nodosum leprosum.
    Walker SL; Waters MF; Lockwood DN
    Lepr Rev; 2007 Sep; 78(3):197-215. PubMed ID: 18035771
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Postpartum weight loss in overweight and obese women using the etonogestrel subdermal implant: a pilot study.
    Griffin L; Hammond C; Liu D; Rademaker AW; Kiley J
    Contraception; 2017 Jun; 95(6):564-570. PubMed ID: 28238839
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Acceptability of long-acting, progestin-only contraception in Europe: a two-year prospective, non-interventional study.
    Short M; Dallay D; Omokanye S; Stauch K; Inki P
    Eur J Contracept Reprod Health Care; 2014 Feb; 19(1):29-38. PubMed ID: 24289528
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Pentoxifylline in the treatment of erythema nodosum leprosum: results of an open study].
    de Carsalade GY; Achirafi A; Flageul B
    Acta Leprol; 2003; 12(3):117-22. PubMed ID: 15040702
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Subdermal contraceptive implants.
    Peralta O; Diaz S; Croxatto H
    J Steroid Biochem Mol Biol; 1995 Jun; 53(1-6):223-6. PubMed ID: 7626459
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Potential of thalidomide and thalidomide analogues as immunomodulatory drugs in leprosy and leprosy reactions.
    Kaplan G
    Lepr Rev; 2000 Dec; 71 Suppl():S117-20. PubMed ID: 11201867
    [No Abstract]   [Full Text] [Related]  

  • 52. Impact of an implantable steroid contraceptive (etonogestrel-releasing implant) on quality of life and sexual function: a preliminary study.
    Di Carlo C; Sansone A; De Rosa N; Gargano V; Tommaselli GA; Nappi C; Bifulco G
    Gynecol Endocrinol; 2014 Jan; 30(1):53-6. PubMed ID: 24131079
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Twelve-month discontinuation of etonogestrel implant in an outpatient pediatric setting.
    Berlan E; Mizraji K; Bonny AE
    Contraception; 2016 Jul; 94(1):81-6. PubMed ID: 26948183
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Twelve-month Continuation of the Etonogestrel Implant in Adolescents With Polycystic Ovary Syndrome.
    Buyers E; Sass AE; Severn CD; Pyle L; Cree-Green M
    J Pediatr Adolesc Gynecol; 2021 Feb; 34(1):33-39. PubMed ID: 32919086
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Thalidomide--the way forward.
    Gardner-Medwin JM; Powell RJ
    Postgrad Med J; 1994 Dec; 70(830):860-2. PubMed ID: 7870630
    [No Abstract]   [Full Text] [Related]  

  • 56. Changes in body composition in women using long-acting reversible contraception.
    Silva Dos Santos PN; Madden T; Omvig K; Peipert JF
    Contraception; 2017 Apr; 95(4):382-389. PubMed ID: 28041992
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Body composition and bone mineral density in users of the etonogestrel-releasing contraceptive implant.
    Modesto W; Dal Ava N; Monteiro I; Bahamondes L
    Arch Gynecol Obstet; 2015 Dec; 292(6):1387-91. PubMed ID: 26088190
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effective treatment of erythema nodosum leprosum with thalidomide is associated with immune stimulation.
    Haslett PA; Roche P; Butlin CR; Macdonald M; Shrestha N; Manandhar R; Lemaster J; Hawksworth R; Shah M; Lubinsky AS; Albert M; Worley J; Kaplan G
    J Infect Dis; 2005 Dec; 192(12):2045-53. PubMed ID: 16288366
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intra-abortion contraception with etonogestrel subdermal implant.
    Barros Pereira I; Carvalho RM; Graça LM
    Eur J Obstet Gynecol Reprod Biol; 2015 Feb; 185():33-5. PubMed ID: 25522115
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of etonogestrel implant beyond approved duration: prolonged contraceptive effectiveness.
    Ribeiro BC; Nogueira-Silva C; Afonso H; Silva PO; Reis ID
    Eur J Contracept Reprod Health Care; 2018 Aug; 23(4):309-310. PubMed ID: 30203680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.